Sign In
Buy ESSA
$20.61
+0 (+0%)
At Close: Oct 23, 2025
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
12:00pm, Saturday, 16'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advise
ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
05:00pm, Thursday, 14'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible vi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
04:30pm, Thursday, 14'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advise
ESSA Pharma Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - EPIX
05:15pm, Tuesday, 12'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible vi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
04:15pm, Tuesday, 12'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advise
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
04:30pm, Friday, 01'st Nov 2024
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to c
Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysi
ESSA Bancorp, Inc. Announces Fiscal Fourth Quarter, Full Year 2024 Financial Results
04:31pm, Wednesday, 23'rd Oct 2024
STROUDSBURG, PA / ACCESSWIRE / October 23, 2024 / ESSA Bancorp, Inc. (the "Company") (NASDAQ:ESSA), the holding company for ESSA Bank & Trust (the "Bank"), a $2.2 billion asset financial institution p
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
05:19pm, Friday, 13'th Sep 2024
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
04:05pm, Wednesday, 11'th Sep 2024
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
ESSA Bancorp, Inc. Declares Quarterly Dividend
04:31pm, Wednesday, 28'th Aug 2024
STROUDSBURG, PA / ACCESSWIRE / August 28, 2024 / ESSA Bancorp, Inc. (NASDAQ Global MarketSM:ESSA), the holding company for ESSA Bank & Trust, today announced that its Board of Directors declared a div
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
07:00am, Monday, 05'th Aug 2024
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase
Essa Bancorp (ESSA) Lags Q3 Earnings and Revenue Estimates
07:00pm, Wednesday, 24'th Jul 2024
Essa Bancorp (ESSA) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.45 per share a year ago.
Essa Bancorp (ESSA) Moves 5.4% Higher: Will This Strength Last?
08:50am, Wednesday, 17'th Jul 2024
Essa Bancorp (ESSA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
04:05pm, Monday, 08'th Jul 2024
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing no
